Early phase-II semi double-blind study of the new alkaline propanolamine derivative enciprazine (short communication).
A new alkaline propanolamine derivative, enciprazine, was tested in an early phase-II semi double-blind placebo-controlled A-B-A design to verify the hypothesis that the substance may have tranquilizing properties. No sedative or anxiolytic effect comparable to minor or major tranquilizers could be observed. According to clinical impression some patients showed an improved goal orientation and self-control which could be effects worth to be followed up.
Linden
M
M
Psychiatrische Klinik und Poliklinik, Freien Universität Berlin, Germany.
Helmchen
H
H
Müller-Oerlinghausen
B
B
D000328:Adult; D001007:Anxiety / Q000188:drug therapy; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D009497:Neurotic Disorders / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011897:Random Allocation; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use*
D010879:Piperazines; D014149:Tranquilizing Agents; C057238:enciprazine